|1.||Potter, Barry V L: 9 articles (10/2015 - 01/2006)|
|2.||Purohit, Atul: 9 articles (10/2015 - 01/2006)|
|3.||Reed, Michael J: 9 articles (10/2015 - 01/2006)|
|4.||Newman, Simon P: 8 articles (10/2015 - 01/2006)|
|5.||Foster, Paul A: 8 articles (10/2015 - 01/2008)|
|6.||Leese, Mathew P: 7 articles (10/2015 - 01/2006)|
|7.||Day, Joanna M: 3 articles (01/2013 - 01/2006)|
|8.||Ho, Yaik T: 3 articles (10/2009 - 01/2008)|
|9.||Foster, P A: 3 articles (02/2009 - 12/2007)|
|10.||Purohit, A: 3 articles (02/2009 - 12/2007)|
03/01/2008 - "However, this was not translated to the tumor efficacy studies where STX140 at 20 mg/kg in either vehicle caused a significant reduction in tumor volume. "
05/01/2008 - "These studies highlight the activity of two orally bioavailable anti-cancer agents one of which, STX140, may offer a significant clinical advantage over existing drugs as a common dose limiting factor, haemotoxicity, may be minimised."
01/01/2013 - "STX140 blocked 47% of tumors developing and significantly inhibited growth of tumors that did develop. "
08/01/2008 - "In contrast, the microtubule disruptor STX140 reduced tumor growth by 55%. "
02/10/2009 - "In conclusion, STX140, a promising orally bioavailable anti-cancer agent in pre-clinical development, is highly efficacious in BCRP-expressing xenografts. "
|2.||Breast Neoplasms (Breast Cancer)
03/01/2008 - "A new micronized formulation of 2-methoxyestradiol-bis-sulfamate (STX140) is therapeutically potent against breast cancer."
03/01/2008 - "The new micronized formulation of STX140 is orally bioavailable and efficacious at inhibiting MDA-MB-231 breast tumor growth."
03/01/2008 - "A new micronized formulation of STX140 has now been developed and its pharmacokinetics (PK) in rats and effect on MDA-MB-231 breast cancer growth in nude mice was investigated. "
03/01/2008 - "For the tumor efficacy studies, female nude mice were inoculated with MDA-MB-231 breast cancer cells and then treated orally with a range of doses of STX140. "
12/17/2007 - "2-Methoxy-3-O-sulphamoyl-17beta-cyanomethyl-oestra-1,3,5(10)-triene (STX641), 2-methoxy-3-hydroxy-17beta-cyanomethyl-oestra-1,3,5(10)-triene (STX640) and 2-methoxyoestradiol-3,17-O,O-bis-sulphamate (STX140) were all potent inhibitors of cell proliferation in a panel of prostate and breast cancer cell lines. "
|3.||Peripheral Nervous System Diseases (PNS Diseases)
01/01/2013 - "Furthermore, paclitaxel, but not STX140, induced significant peripheral neuropathy and neutropenia. "
01/01/2013 - "STX140, a compound previously shown to have excellent efficacy against many tumors, is here compared to paclitaxel in three translational in vivo breast cancer models, a rat model of peripheral neuropathy, and through pharmacological testing. "
|4.||Prostatic Neoplasms (Prostate Cancer)
10/01/2009 - "STX140 and STX641 cause apoptosis via the intrinsic mitochondrial pathway and down-regulate survivin and XIAP expression in ovarian and prostate cancer cells."
12/17/2007 - "This study demonstrates that STX641 and STX140 have considerable potential for the treatment of hormone-independent breast and prostate cancer. "
12/02/2008 - "The combination of STX140 and 2DG in LNCaP cells under normoxia or hypoxia inhibited proliferation to a greater extent than either compound alone. "
10/01/2015 - "Despite inhibiting nuclear HIF1α protein accumulation under hypoxia in vitro, STX140 and STX243 did not significantly regulate the expression of four out of five HIF1α-regulated genes in vitro and in vivo. "
10/01/2015 - "The effects of STX140, STX243 and the parental compound 2-methoxyestradiol (STX66) on HIF1α and HIF2α protein expression were assessed in vitro in MCF-7 and MDA-MB-231 cells cultured under hypoxia. "
|3.||2- methoxy- 3- O- sulfamoyl- 17- cyanomethylestra- 1,3,5(10)- triene
|5.||Caspase 3 (Caspase-3)
|6.||Steryl-Sulfatase (Steroid Sulfatase)
|8.||2- methoxyoestra- 1,3,5(10),16- tetraene- 3- carboxamide
|1.||Heterologous Transplantation (Xenotransplantation)